Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-PNT2002 + pembrolizumab
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
177Lu-PNT2002 + pembrolizumab is an investigational combination therapy being evaluated for the treatment of metastatic clear cell renal cell carcinoma (ccRCC). 177Lu-PNT2002, also known as 177Lu-PSMA I&T, is a radiopharmaceutical that targets the prostate-specific membrane antigen (PSMA), which is expressed on the neovasculature of various solid tumors, including RCC. It delivers the beta-emitting radioisotope lutetium-177 directly to the tumor site. Pembrolizumab is a well-established immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) receptor. The combination is being studied by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in a Phase 1b/2 trial (NCT05973110) to determine if the localized radiation from the radioligand therapy can enhance the efficacy of immunotherapy in patients who have previously progressed on anti-PD-1 or PD-L1 treatments.
- Other names
- 177Lu-PNT2002 plus pembrolizumab177Lu-PSMA I&T plus pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-PNT2002 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-PNT2002 + pembrolizumab.